Y-Intercept (HK)’s AbbVie ABBV Stock Holding History

Y-Intercept (HK)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18.7M	Sell	74,248 -19,428	-21%	-$4.18M	0.37%	29
2026 Q1	$20.4M	Buy	+93,676	New	+$20.8M	0.39%	20
2025 Q2	–	Sell	-9,251	Closed	-$1.94M	–	1589
2025 Q1	$1.94M	Buy	9,251 +4,322	+88%	+$840K	0.13%	194
2024 Q4	$876K	Buy	+4,929	New	+$906K	0.06%	479
2024 Q3	–	Sell	-12,505	Closed	-$2.14M	–	1240
2024 Q2	$2.14M	Buy	+12,505	New	+$2.07M	0.12%	231
2024 Q1	–	Sell	-6,943	Closed	-$1.08M	–	1314
2023 Q4	$1.08M	Buy	+6,943	New	+$1.01M	0.1%	294
2023 Q3	–	Sell	-33,789	Closed	-$4.55M	–	1002
2023 Q2	$4.55M	Buy	+33,789	New	+$4.95M	0.48%	11
2022 Q4	–	Sell	-10,765	Closed	-$1.44M	–	947
2022 Q3	$1.44M	Buy	+10,765	New	+$1.54M	0.14%	211
2021 Q3	–	Sell	-3,843	Closed	-$433K	–	616
2021 Q2	$433K	Buy	3,843 +1,284	+50%	+$145K	0.11%	299
2021 Q1	$273K	Buy	+2,559	New	+$274K	0.07%	443

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Y-Intercept (HK)'s ABBV Position: Q2 2026 in Review

Y-Intercept (HK) reduced its AbbVie (ABBV) stake by 21% in Q2 2026, selling an estimated $4.18M and leaving 74,248 shares worth $18.7M. The position accounts for 0.37% of the portfolio, ranked #29.

Y-Intercept (HK) first reported a position in ABBV in Q1 2021 and has held it in 10 quarters since. The position peaked at $20.4M in Q1 2026. 1,483 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Y-Intercept (HK) held 74,248 shares of AbbVie worth $18.7M as of Q2 2026.
Y-Intercept (HK) sold 19,428 AbbVie shares in Q2 2026, an estimated $4.18M.
AbbVie made up 0.37% of Y-Intercept (HK)'s portfolio in Q2 2026, its #29 holding.
Y-Intercept (HK) first reported a position in AbbVie in Q1 2021 and has held it in 10 quarters since.
Y-Intercept (HK)'s AbbVie position peaked at $20.4M in Q1 2026.
1,483 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.